Press Release

Zetagen Therapeutics, Inc. Awarded $225,000 USD Grant from NIAMS for Phase I Study of Novel Osteoinductive Lumbar Fusion Implant for Small Molecule-Based

11 September 2019
  • Award comes from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH)
  • U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
  • Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Event) (SRE’s) and osteologic interventions

September 11, 2019 – (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today its award of $225,000 USD from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH). The grant will be used for a Phase I validation study of a novel, surgical implant for use with the Company’s small-molecule ZetaFuse™. The implant is designed to repair damaged bone through stem cell activation.

We are extremely pleased to be recognized by the NIAMS, allowing us to enter our next phase of research,” said Joe C. Loy, CEO of Zetagen Therapeutics, Inc. “This study further builds on our earlier validation studies, allowing us to now focus on how to successfully repair damaged bone by activating the body’s own stem cells – something which can potentially be applied beyond osteolytic cancers to other orthopedic interventions.”

The NIAMS grant is part of the Small Business Innovation Research Program (SBIR), a three phase award system created by the Federal Government for small businesses to engage in research and development that has the potential for commercialization and public benefit. Zetagen exclusively-licensed its platform technology from the State University of New York in 2016.

All News

About zetagen Therapeutics

Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs.

The company's pipeline encompasses several oncological candidates targeting metastatic and primary cancers for breast, lung, brain, prostate, and sarcomas with such drugs as ZetaMet™ (Zeta-BC-003), ZetaMet-P™ (Zeta-PC-004) and ZetaMAST™ (Zeta-MBC-005).

Forward-Looking Statements

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.
Source: Zetagen Therapeutics, Inc.
SUNY Biotech Accelerator
841 E Fayette Street, Suite 1100
Syracuse, NY 13210
Investor Inquiries:
Zetagen Therapeutics, Inc.

Media Inquiries:
Mog & Springer Communications on Behalf of Zetagen Therapeutics, Inc.
Elizabeth Harness, Principal
Phone: +1-585-435-7379